Search Result

Results for "

FABPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Apoptosis (3) Autophagy (1) CaMK (1) Carnitine Palmitoyltransferase (CPT) (1) Caspase (2) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (1) ERK (1) FABP (22) FAK (1) Ferroptosis (1) Fluorescent Dye (5) FXR (1) GLUT (1) HSP (1) IAP (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JNK (1) MDM-2/p53 (1) Mitochondrial Metabolism (1) mTOR (1) Nuclear Hormone Receptor 4A/NR4A (1) PARP (1) PERK (1) Phosphatase (1) PI3K (1) Piezo Channel (1) PPAR (3) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Small Interfering RNA (siRNA) (23) SOD (1) VEGFR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (5) Inflammation/Immunology (10) Metabolic Disease (18)
Oligonucleotides:	Rat Pre-designed siRNA Sets (7) Mouse Pre-designed siRNA Sets (7) Human Pre-designed siRNA Sets (9) siRNAs (23)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101903

BMS-309403 Maximum Cited Publications 25 Publications Verification	FABP	Cardiovascular Disease Metabolic Disease
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .

HY-101903A

BMS-309403 sodium Maximum Cited Publications 25 Publications Verification	FABP	Cardiovascular Disease Metabolic Disease
BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .

HY-D1736

BODIPY FL-C16	Fluorescent Dye	Others
BODIPY FL-C16 is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with K_d values of 270 nM and 330 nM, respectively. BODIPY FL-C16 is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .

HY-145990

FABPs ligand 6 1 Publications Verification MF6	FABP	Inflammation/Immunology
FABPs ligand 6 (MF6) is an *FABP5* and *FABP7* inhibitor with K_D values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research .

HY-148665

FABP-IN-2	FABP	Others
FABP-IN-2 is a novel *FABP3* ligand. FABP-IN-2 inhibits FABP3/FABP4 with an IC₅₀ of 1.16 μM and 4.27 μM respectively .

HY-N2445

Flavokawain C 4 Publications Verification	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK	Cancer
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates *FABP4, induces autophagy* in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-161702

RO6806051	FABP	Inflammation/Immunology
RO6806051 is a selectivity *FABP4* and *FABP5* inhibitor with human FABP4 K_i values of 0.011 μM and 0.23 μM, and human FABP5 K_i values of 0.086 μM and 1.17 μM. RO6806051 can be used for the research of inflammation-related diseases .

HY-W040255

1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine PGPC	Ferroptosis FABP Caspase Interleukin Related Apoptosis	Inflammation/Immunology
1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is an oxidized phospholipid. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine reduces the viability of HUVECs, increases the levels of ferrous ions and lipid peroxidation, promotes the production of superoxide anions, and decreases the levels of glutathione and GPX4 in cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine upregulates the mRNA and protein levels of *FABP3* in HUVECs, impairs mitochondrial membrane potential, and induces ferroptosis-related changes as well as mitochondrial dysfunction and damage. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine activates caspase-11 and promotes the continuous release of IL-1β from macrophages and dendritic cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibits the proliferation of aortic smooth muscle cells and induces apoptosis in these cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is applicable to relevant research on atherosclerosis .

HY-158127

FABP1-IN-1 1 Publications Verification	FABP	Metabolic Disease Inflammation/Immunology
FABP1-IN-1 (44) is a selective *FABP1* inhibitor, with an IC₅₀ of 4.46 μM. FABP1-IN-1 (44) can be used for the research of NASH .

HY-W012865

Tartronic acid	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite FABP PPAR	Metabolic Disease
Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of *FABP-4, PPARγ* and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research .

HY-N12540

Monogalactosyldiacylglycerol MGDG	DNA/RNA Synthesis Apoptosis	Others
Monogalactosyldiacylglycerol (MGDG) is a galactolipid with anti-inflammatory and anticancer activities, which is found in photosynthetic organisms. Monogalactosyldiacylglycerol is a potent DNA polymerase inhibitor with pro-apoptotic activity. Monogalactosyldiacylglycerol inhibits the synthesis of LPS (HY-D1056)-induced inflammation-related proteins (Ex-FABP, Avidin, Serum Amyloid A). Monogalactosyldiacylglycerol exerts an anti-proliferative effect on chicken articular chondrocytes . Monogalactosyldiacylglycerol can be used in research related to osteoarthritis, cancer and inflammatory diseases .

HY-165607S

MCB-22-174	Piezo Channel Isotope-Labeled Compounds ERK CaMK	Metabolic Disease
MCB-22-174 is a deuterated Piezo1 agonist, with an EC₅₀ value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca ²⁺ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP) .

HY-127049

Arachidonic acid-biotin	Fluorescent Dye	Others
Arachidonic acid-Biotin is a biotin-labeled Arachidonic acid (HY-109590) that can be used to detect complexes of arachidonic acid with protein binding partners such as fatty acid binding proteins (FABPs) .

HY-163032

FABP4-IN-3	FABP	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FABP4-IN-3 (compound C3) is a highly selective *FABP4* inhibitor (FABP4 K_i = 25 ± 3 ^a nM, FABP3 K_i = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .

HY-160457

FABP4/5-IN-5	FABP	Metabolic Disease
FABP4/5-IN-5 (compound D9) is a potent inhibitor of *FABP4 and FABP*5,? with the IC₅₀s of 4.68 μM and 10.72 μM, respectively.FABP4/5-IN-5 plays an important role in metabolism disorder like diabetes mellitus .

HY-RS04661

FABP5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP5 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP5 Human Pre-designed siRNA Set A FABP5 Human Pre-designed siRNA Set A

HY-RS16621

Fabp4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp4 Mouse Pre-designed siRNA Set A Fabp4 Mouse Pre-designed siRNA Set A

HY-149831

ZLY28	FXR	Metabolic Disease
ZLY28 is the first-in-class intestinal restricted and orally active FXR and *FABP1* dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-P4115

CooP	FABP	Cancer
CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .

HY-172883

ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
ABP/PPAR modulator 1 is an orally active *FABP* and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-172883A

(E/Z)-ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
(E/Z)-ABP/PPAR modulator 1 is a mixture of the E and Z isomers of ABP/PPAR modulator 1 (HY-172883). ABP/PPAR modulator 1 is an orally active *FABP* and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-149953

FABP4-IN-2	FABP	Inflammation/Immunology
FABP4-IN-2 (Compd 10g) is a selective and orally active *FABP4* inhibitor with the K_i values of 0.51 μM for FABP4, 33.01 μM for FABP3. FABP4-IN-2 can be used in the research of inflammation-related diseases .

HY-178471

FABP4/5-IN-6	FABP Interleukin Related	Metabolic Disease Inflammation/Immunology
FABP4/5-IN-6 is an orally active, potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM), showing low selectivity over FABP3 (Ki = 59.72 μM). FABP4/5-IN-6 inhibits the secretion of MCP-1 and IL-6 in Lipopolysaccharides (HY-D1056) (LPS)-induced THP-1 macrophage. FABP4/5-IN-6 exhibits significant anti-inflammatory effects and attenuates LPS-induced liver injury. FABP4/5-IN-6 has low hERG inhibition (LD₅₀ > 2000 mg/kg). FABP4/5-IN-6 can be used for the study of Inflammation-related diseases .

HY-160456

FABP4/5-IN-4	FABP	Metabolic Disease
FABP4/5-IN-4 (compound E1) is a potent inhibitor of *FABP4 and FABP5, with the IC₅₀s of 3.78 μM and 5.72 μM, respectively. FABP*4/5-IN-4 plays an important role in metabolism disorder like diabetes mellitus .

HY-161892

FABP4-IN-4	FABP	Metabolic Disease Inflammation/Immunology
FABP4-IN-4 (Compound 30) is an orally active inhibitor for *FABP, with IC₅₀* of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .

HY-117562

*a-FABP-IN-1*	FABP	Metabolic Disease
a-FABP-IN-1 (Compound 5g) is a potent and selective human adipocyte fatty acid-binding protein (a-FABP) inhibitor with a K_i below 1.0 nM. a-FABP-IN-1 inhibits the pro-inflammatory cytokine production .

HY-RS23414

Fabp3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp3 Rat Pre-designed siRNA Set A Fabp3 Rat Pre-designed siRNA Set A

HY-RS04659

FABP3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP3 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP3 Human Pre-designed siRNA Set A FABP3 Human Pre-designed siRNA Set A

HY-RS23039

Fabp5 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp5 Rat Pre-designed siRNA Set A Fabp5 Rat Pre-designed siRNA Set A

HY-RS23056

Fabp4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp4 Rat Pre-designed siRNA Set A Fabp4 Rat Pre-designed siRNA Set A

HY-RS04662

FABP6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP6 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP6 Human Pre-designed siRNA Set A FABP6 Human Pre-designed siRNA Set A

HY-RS04664

FABP9 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP9 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP9 Human Pre-designed siRNA Set A FABP9 Human Pre-designed siRNA Set A

HY-RS17252

Fabp1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp1 Mouse Pre-designed siRNA Set A Fabp1 Mouse Pre-designed siRNA Set A

HY-RS16605

Fabp5 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp5 Mouse Pre-designed siRNA Set A Fabp5 Mouse Pre-designed siRNA Set A

HY-RS17908

Fabp7 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp7 Mouse Pre-designed siRNA Set A Fabp7 Mouse Pre-designed siRNA Set A

HY-RS24998

Fabp6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp6 Rat Pre-designed siRNA Set A Fabp6 Rat Pre-designed siRNA Set A

HY-RS04657

FABP12 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP12 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP12 Human Pre-designed siRNA Set A FABP12 Human Pre-designed siRNA Set A

HY-RS04663

FABP7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP7 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP7 Human Pre-designed siRNA Set A FABP7 Human Pre-designed siRNA Set A

HY-RS23706

Fabp1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp1 Rat Pre-designed siRNA Set A Fabp1 Rat Pre-designed siRNA Set A

HY-RS24754

Fabp2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp2 Rat Pre-designed siRNA Set A Fabp2 Rat Pre-designed siRNA Set A

HY-RS16971

Fabp3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp3 Mouse Pre-designed siRNA Set A Fabp3 Mouse Pre-designed siRNA Set A

HY-RS04660

FABP4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP4 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP4 Human Pre-designed siRNA Set A FABP4 Human Pre-designed siRNA Set A

HY-RS04658

FABP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP2 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP2 Human Pre-designed siRNA Set A FABP2 Human Pre-designed siRNA Set A

HY-RS04656

FABP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FABP1 Human Pre-designed siRNA Set A contains three designed siRNAs for FABP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FABP1 Human Pre-designed siRNA Set A FABP1 Human Pre-designed siRNA Set A

HY-101903R

BMS-309403 (Standard)	Reference Standards FABP	Cardiovascular Disease Metabolic Disease
BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .

HY-101903AR

BMS-309403 sodium (Standard)	Reference Standards FABP	Cardiovascular Disease Metabolic Disease
BMS-309403 (sodium) (Standard) is the analytical standard of BMS-309403 (sodium). This product is intended for research and analytical applications. BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .

HY-D2857

NBD-Stearic acid	Fluorescent Dye	Metabolic Disease
NBD-Stearic acid is a stearic acid labeled with a nitrobenzoxadiazole (NBD) fluorophore. NBD-Stearic acid can be used as a probe for fatty acid uptake or the the ligand binding sites of fatty acid and sterol carrier proteins (FABP)

HY-N15885

12-NBD Stearate	Fluorescent Dye FABP Phosphatase	Metabolic Disease
12-NBD Stearate is a fluorescent fatty acid analogue. 12-NBD Stearate binds to fatty acid binding protein (FABP) and sterol carrier protein-2 (SCP-2). Overexpressing sterol carrier protein-2 (SCP-2) 15-kDa isoform enhances 12-NBD Stearate transport. 12-NBD Stearate is a tool for microscopic long chain fatty acids (LCFA) uptake and internalization studies .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

HY-RS18516

Fabp6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fabp6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fabp6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fabp6 Mouse Pre-designed siRNA Set A Fabp6 Mouse Pre-designed siRNA Set A

Cat. No.	Product Name	Type

HY-D1736

BODIPY FL-C16

Fluorescent Dye

BODIPY FL-C16 is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with K_d values of 270 nM and 330 nM, respectively. BODIPY FL-C16 is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .

HY-D2857

NBD-Stearic acid	Fluorescent Dye
NBD-Stearic acid is a stearic acid labeled with a nitrobenzoxadiazole (NBD) fluorophore. NBD-Stearic acid can be used as a probe for fatty acid uptake or the the ligand binding sites of fatty acid and sterol carrier proteins (FABP)

HY-DY1102

BODIPY FL-C16 (solution)

Fluorescent Dye

BODIPY FL-C16 (solution) is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 (solution) also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with K_d values of 270 nM and 330 nM, respectively. BODIPY FL-C16 (solution) is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .
Solvent and concentration: DMSO: 5 mM

Cat. No.	Product Name	Type

HY-W040255

1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine

PGPC

Biochemical Assay Reagents

1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is an oxidized phospholipid. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine reduces the viability of HUVECs, increases the levels of ferrous ions and lipid peroxidation, promotes the production of superoxide anions, and decreases the levels of glutathione and GPX4 in cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine upregulates the mRNA and protein levels of FABP3 in HUVECs, impairs mitochondrial membrane potential, and induces ferroptosis-related changes as well as mitochondrial dysfunction and damage. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine activates caspase-11 and promotes the continuous release of IL-1β from macrophages and dendritic cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibits the proliferation of aortic smooth muscle cells and induces apoptosis in these cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is applicable to relevant research on atherosclerosis .

Cat. No.	Product Name	Target	Research Area

HY-P4115

CooP	FABP	Cancer
CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates *FABP4, induces autophagy* in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-N12540

Monogalactosyldiacylglycerol MGDG	Structural Classification other families Oplismenus burmannii Plants Lipid Source Classification	DNA/RNA Synthesis Apoptosis
Monogalactosyldiacylglycerol (MGDG) is a galactolipid with anti-inflammatory and anticancer activities, which is found in photosynthetic organisms. Monogalactosyldiacylglycerol is a potent DNA polymerase inhibitor with pro-apoptotic activity. Monogalactosyldiacylglycerol inhibits the synthesis of LPS (HY-D1056)-induced inflammation-related proteins (Ex-FABP, Avidin, Serum Amyloid A). Monogalactosyldiacylglycerol exerts an anti-proliferative effect on chicken articular chondrocytes . Monogalactosyldiacylglycerol can be used in research related to osteoarthritis, cancer and inflammatory diseases .

HY-N15885

12-NBD Stearate	Lipid	Fluorescent Dye FABP Phosphatase
12-NBD Stearate is a fluorescent fatty acid analogue. 12-NBD Stearate binds to fatty acid binding protein (FABP) and sterol carrier protein-2 (SCP-2). Overexpressing sterol carrier protein-2 (SCP-2) 15-kDa isoform enhances 12-NBD Stearate transport. 12-NBD Stearate is a tool for microscopic long chain fatty acids (LCFA) uptake and internalization studies .

Cat. No.	Product Name	Chemical Structure

HY-165607S

MCB-22-174

MCB-22-174 is a deuterated Piezo1 agonist, with an EC₅₀ value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca ²⁺ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FABPs

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products